Cannabis and Cannabinoid Research
Cannabis and Cannabinoid Research is the premier journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. The Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies. Cannabis and Cannabinoid Research is the leading source for authoritative cannabis and cannabinoid research, discussion, and debate.
Cannabis and Cannabinoid Research coverage includes:
- Biochemical process of the endocannabinoid system
- Cannabinoid receptors and signaling
- Pharmaceuticals based on cannabis and cannabinoids
- Optimal dosing and drug delivery
- Short- and long-term effects on the brain and behavior
- Toxicological studies
- Analgesic effects, including neuropathic pain and chronic nerve injury
- Neurological disorders, including epilepsy, multiple sclerosis, and glaucoma
- Use of cannabis as antinauseants and antispasmodics
- Immune function and chronic inflammation, including HIV
- Cancer and cancer-related treatment
- Screening and assessment for marijuana misuse and addiction
- Social, behavioral, and public health impact
- Ethics, regulation, legalization, and public policy
Cannabis and Cannabinoid Research is under the editorial leadership of Daniele Piomelli, PhD, the Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry at University of California, Irvine. The editorial board is comprised of leading investigators in the field from around the world. View the entire editorial board here
Audience: Pharmacologists and psychopharmacologists, toxicologists, biochemists, neurologists, psychiatrists, physicians, and other healthcare practitioners, addiction specialists, and regulators and policymakers, among others
Study: CBD may help block pain-signalling pathways
There’s no shortage of anecdotal evidence about the efficacy of cannabidiol (CBD) for treating pain, but a new study offers further scientific insight into how the compound interacts with nerve cells.
Published in the Journal of Pain Research, the study suggests that CBD may help block pain-signalling pathways.
Researchers found that lab-cultured rat neurons treated with CBD were less sensitive to capsaicin, the active compound in chili peppers. The nerve cells treated with CBD saw an influx of calcium and reduced levels of the pain-signalling molecule cAMP, a key signalling molecule in the pain pathway, reports Imperial College London.
Access to medical cannabis remains a challenge in the U.K., argues mother of chronically ill child
5 ways medical cannabis can help with chronic pain
Cannabis use disorder has both genetic and biological underpinnings: researchers
Study: CBD may help block pain-signalling pathways Back to video
Researchers believe this might help explain the therapeutic effect of CBD in patients with acute and chronic pain.
The study was led by Mikael Sodergren, a senior clinical lecturer at the university, a hepatobiliary consultant and a pancreatic surgeon at Imperial College Healthcare NHS Trust.
Sodergren is currently leading research, from pre-clinical to clinical studies, focusing on cannabis-based products to treat pain, inflammation and cancer.
Medical cannabis became legal in the U.K. in 2018, but advocates say it is difficult to access and prohibitively expensive.
A recent poll of more than 13,000 U.K. residents found that nearly half — 46 per cent — were unaware that medical cannabis is legal. Studies like Sodergren’s could help change that.
It’s also in line with other research, including a 2008 review published in Therapeutics and Clinical Risk Management, that found cannabinoids have shown “great promise” as an adjunct therapy for difficult-to-treat pain.